Raymond James Financial Inc. Invests $19.08 Million in ADMA Biologics, Inc. (NASDAQ:ADMA)

Raymond James Financial Inc. acquired a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 1,112,275 shares of the biotechnology company’s stock, valued at approximately $19,076,000. Raymond James Financial Inc. owned about 0.47% of ADMA Biologics as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of ADMA Biologics by 13.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock worth $13,171,000 after buying an additional 80,400 shares during the last quarter. Lord Abbett & CO. LLC acquired a new stake in ADMA Biologics in the 3rd quarter valued at $61,858,000. EWG Elevate Inc. acquired a new stake in ADMA Biologics in the 4th quarter valued at $480,000. Citigroup Inc. increased its holdings in ADMA Biologics by 251.7% in the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock valued at $7,741,000 after purchasing an additional 277,138 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in ADMA Biologics by 1,144.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock valued at $51,016,000 after purchasing an additional 2,613,482 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Up 2.9 %

Shares of NASDAQ ADMA opened at $18.43 on Monday. ADMA Biologics, Inc. has a 12-month low of $5.88 and a 12-month high of $23.64. The company has a market cap of $4.36 billion, a P/E ratio of 65.82 and a beta of 0.60. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a fifty day moving average price of $16.67 and a 200 day moving average price of $17.96.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.